Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?
Introduction and Objectives: The lockdown policy introduced in 2020 to minimize the spread of the COVID-19 pandemic, significantly affected the management and care of patients affected by hepatocellular carcinoma (HCC). The aim of this follow-up study was to determine the 12 months impact of the COV...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-11-01
|
| Series: | Annals of Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268123002442 |
| _version_ | 1827781480408940544 |
|---|---|
| author | Raffaele Brustia Mohamed Bouattour Manon Allaire Marie Lequoy Clémence Hollande Hélène Regnault Lorraine Blaise Nathalie Ganne-Carrié Valérie Vilgrain Edouard Larrey Chetana Lim Olivier Scatton Sanaa El Mouhadi Violaine Ozenne François Paye Pierre Balladur Anthony Dohan Pierre-Philippe Massault Stanislas Pol Marco Dioguardi Burgio Ailton Sepulveda Francois Cauchy Alain Luciani Daniele Sommacale Vincent Leroy Julien Calderaro Francoise Roudot-Thoraval Jean-Charles Nault Giuliana Amaddeo |
| author_facet | Raffaele Brustia Mohamed Bouattour Manon Allaire Marie Lequoy Clémence Hollande Hélène Regnault Lorraine Blaise Nathalie Ganne-Carrié Valérie Vilgrain Edouard Larrey Chetana Lim Olivier Scatton Sanaa El Mouhadi Violaine Ozenne François Paye Pierre Balladur Anthony Dohan Pierre-Philippe Massault Stanislas Pol Marco Dioguardi Burgio Ailton Sepulveda Francois Cauchy Alain Luciani Daniele Sommacale Vincent Leroy Julien Calderaro Francoise Roudot-Thoraval Jean-Charles Nault Giuliana Amaddeo |
| author_sort | Raffaele Brustia |
| collection | DOAJ |
| description | Introduction and Objectives: The lockdown policy introduced in 2020 to minimize the spread of the COVID-19 pandemic, significantly affected the management and care of patients affected by hepatocellular carcinoma (HCC). The aim of this follow-up study was to determine the 12 months impact of the COVID-19 pandemic on the cohort of patients affected by HCC during the lockdown, within six French academic referral centers in the metropolitan area of Paris. Materials and Methods: We performed a 12 months follow-up of the cross-sectional study cohort included in 2020 on the management of patients affected by HCC during the first six weeks of the COVID-19 pandemic (exposed), compared to the same period in 2019 (unexposed). Overall survival were compared between the groups. Predictors of mortality were analysed with Cox regression. Results: From the initial cohort, 575 patients were included (n = 263 Exposed_COVID, n = 312 Unexposed_COVID). Overall and disease free survival at 12 months were 59.9 ± 3.2% vs. 74.3 ± 2.5% (p<0.001) and 40.2 ± 3.5% vs. 63.5 ± 3.1% (p<0.001) according to the period of exposure (Exposed_COVID vs. Unexposed_COVID, respectively). Adjusted Cox regression revealed that the period of exposure (Exposed_COVID HR: 1.79, 95%CI (1.36, 2.35) p<0.001) and BCLC stage B, C and D (BCLC B HR: 1.82, 95%CI (1.07, 3.08) p = 0.027 - BCLC C HR: 1.96, 95%CI (1.14, 3.38) p = 0.015 - BCLC D HR: 3.21, 95%CI (1.76, 5.85) p<0.001) were predictors of death. Conclusions: Disruption of routine healthcare services because of the pandemic translated to reduced 1 year overall and disease-free survival among patients affected by HCC, in the metropolitan area of Paris, France. |
| first_indexed | 2024-03-11T15:19:18Z |
| format | Article |
| id | doaj.art-8f6ec44b4e9548788bba1e30c48fda30 |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-03-11T15:19:18Z |
| publishDate | 2023-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-8f6ec44b4e9548788bba1e30c48fda302023-10-29T04:19:30ZengElsevierAnnals of Hepatology1665-26812023-11-01286101141Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?Raffaele Brustia0Mohamed Bouattour1Manon Allaire2Marie Lequoy3Clémence Hollande4Hélène Regnault5Lorraine Blaise6Nathalie Ganne-Carrié7Valérie Vilgrain8Edouard Larrey9Chetana Lim10Olivier Scatton11Sanaa El Mouhadi12Violaine Ozenne13François Paye14Pierre Balladur15Anthony Dohan16Pierre-Philippe Massault17Stanislas Pol18Marco Dioguardi Burgio19Ailton Sepulveda20Francois Cauchy21Alain Luciani22Daniele Sommacale23Vincent Leroy24Julien Calderaro25Francoise Roudot-Thoraval26Jean-Charles Nault27Giuliana Amaddeo28Department of Digestive and Hepato-pancreatic-biliary Surgery, AP-HP, Hôpital Henri-Mondor, F-94010 Créteil, France; INSERM U955, Team ''Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers'', Créteil, France – Assistance Publique-Hôpitaux de Paris, France; Corresponding authors.Département d'Oncologie Hépatique, AP-HP, Hôpital Beaujon, F-92110 Clichy, FranceSorbonne Université, Paris, France; Hepatology and Liver transplantation department, Hôpital Pitié Salpêtrière, Sorbonne Université, AP-HP, Hôpital de la Pitié–Salpêtrière, F-75013 Paris, FranceDepartment of Hepatology, AP-HP, Hôpital Saint Antoine, F-75012 Paris, FranceDepartment of Hepatology, AP-HP, Hôpital Cochin, F-75014 Paris, FranceDepartment of Hepatology, AP-HP, Hôpital Henri-Mondor, F-94010 Créteil, FranceService d'hépatologie, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bondy, FranceService d'hépatologie, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bondy, France; Centre de Recherche des Cordeliers, Inserm, Sorbonne Université, Université Paris, INSERM UMR 1138 Functional Genomics of Solid Tumors laboratory, F-75006, Paris, FranceDepartment of Radiology, Hôpital Beaujon, Hôpitaux Universitaires Paris Nord Val de Seine, Assistance-Publique Hôpitaux de Paris, Clichy, France - INSERM U1149 ''centre de recherche sur l'inflammation”, CRI, Paris FranceSorbonne Université, Paris, France; Hepatology and Liver transplantation department, Hôpital Pitié Salpêtrière, Sorbonne Université, AP-HP, Hôpital de la Pitié–Salpêtrière, F-75013 Paris, FranceDigestive and Liver transplantation department, Hôpital Pitié Salpêtrière, Sorbonne Université, AP-HP, Hôpital de la Pitié–Salpêtrière, F-75013 Paris, FranceDepartment of Hepatology, AP-HP, Hôpital Saint Antoine, F-75012 Paris, France; Digestive and Liver transplantation department, Hôpital Pitié Salpêtrière, Sorbonne Université, AP-HP, Hôpital de la Pitié–Salpêtrière, F-75013 Paris, FranceDepartment of Radiology, AP-HP, Hôpital Saint Antoine, F-75012 Paris, FranceDepartment of Hepatology, AP-HP, Hôpital Saint Antoine, F-75012 Paris, FranceDepartment of Digestive Surgery, AP-HP, Hôpital Saint Antoine, F-75012 Paris, FranceDepartment of Digestive Surgery, AP-HP, Hôpital Saint Antoine, F-75012 Paris, FranceDepartment of Radiology, AP-HP, Hôpital Cochin, Université de Paris, F-75014 Paris, FranceDepartment of Digestive Surgery, AP-HP, Hôpital Cochin, Université de Paris, F-75014 Paris, FranceDepartment of Hepatology, AP-HP, Hôpital Cochin, F-75014 Paris, FranceDepartment of Radiology, Hôpital Beaujon, Hôpitaux Universitaires Paris Nord Val de Seine, Assistance-Publique Hôpitaux de Paris, Clichy, France - INSERM U1149 ''centre de recherche sur l'inflammation”, CRI, Paris FranceDigestive and Liver transplantation department, Hôpital Beaujon, Hôpitaux Universitaires Paris Nord Val de Seine, Assistance-Publique Hôpitaux de Paris, Clichy, FranceDigestive and Liver transplantation department, Hôpital Beaujon, Hôpitaux Universitaires Paris Nord Val de Seine, Assistance-Publique Hôpitaux de Paris, Clichy, FranceINSERM U955, Team ''Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers'', Créteil, France – Assistance Publique-Hôpitaux de Paris, France; Department of Radiology, AP-HP, Hôpital Henri-Mondor, F-94010 Créteil, France; Paris Est Créteil University, UPEC, Créteil, FranceDepartment of Digestive and Hepato-pancreatic-biliary Surgery, AP-HP, Hôpital Henri-Mondor, F-94010 Créteil, France; INSERM U955, Team ''Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers'', Créteil, France – Assistance Publique-Hôpitaux de Paris, France; Paris Est Créteil University, UPEC, Créteil, FranceINSERM U955, Team ''Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers'', Créteil, France – Assistance Publique-Hôpitaux de Paris, France; Department of Hepatology, AP-HP, Hôpital Henri-Mondor, F-94010 Créteil, France; Paris Est Créteil University, UPEC, Créteil, FranceUniversité Paris Est Créteil, INSERM, IMRB, F-94010 Créteil, France; Assistance Publique-Hôpitaux de Paris, Henri Mondor-Albert Chenevier University Hospital, Department of Pathology, Créteil, France; Inserm, U955, Team 18, Créteil, France; European Reference Network (ERN) RARE-LIVER, FranceDepartment of Hepatology, AP-HP, Hôpital Henri-Mondor, F-94010 Créteil, FranceService d'hépatologie, Hôpital Jean Verdier, Hôpitaux Universitaires Paris-Seine-Saint-Denis, Assistance-Publique Hôpitaux de Paris, Bondy, France; Centre de Recherche des Cordeliers, Inserm, Sorbonne Université, Université Paris, INSERM UMR 1138 Functional Genomics of Solid Tumors laboratory, F-75006, Paris, FranceINSERM U955, Team ''Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers'', Créteil, France – Assistance Publique-Hôpitaux de Paris, France; Department of Hepatology, AP-HP, Hôpital Henri-Mondor, F-94010 Créteil, France; Paris Est Créteil University, UPEC, Créteil, France; Corresponding authors.Introduction and Objectives: The lockdown policy introduced in 2020 to minimize the spread of the COVID-19 pandemic, significantly affected the management and care of patients affected by hepatocellular carcinoma (HCC). The aim of this follow-up study was to determine the 12 months impact of the COVID-19 pandemic on the cohort of patients affected by HCC during the lockdown, within six French academic referral centers in the metropolitan area of Paris. Materials and Methods: We performed a 12 months follow-up of the cross-sectional study cohort included in 2020 on the management of patients affected by HCC during the first six weeks of the COVID-19 pandemic (exposed), compared to the same period in 2019 (unexposed). Overall survival were compared between the groups. Predictors of mortality were analysed with Cox regression. Results: From the initial cohort, 575 patients were included (n = 263 Exposed_COVID, n = 312 Unexposed_COVID). Overall and disease free survival at 12 months were 59.9 ± 3.2% vs. 74.3 ± 2.5% (p<0.001) and 40.2 ± 3.5% vs. 63.5 ± 3.1% (p<0.001) according to the period of exposure (Exposed_COVID vs. Unexposed_COVID, respectively). Adjusted Cox regression revealed that the period of exposure (Exposed_COVID HR: 1.79, 95%CI (1.36, 2.35) p<0.001) and BCLC stage B, C and D (BCLC B HR: 1.82, 95%CI (1.07, 3.08) p = 0.027 - BCLC C HR: 1.96, 95%CI (1.14, 3.38) p = 0.015 - BCLC D HR: 3.21, 95%CI (1.76, 5.85) p<0.001) were predictors of death. Conclusions: Disruption of routine healthcare services because of the pandemic translated to reduced 1 year overall and disease-free survival among patients affected by HCC, in the metropolitan area of Paris, France.http://www.sciencedirect.com/science/article/pii/S16652681230024422019-nCoVCOVID-19ManagementHepatocellular carcinomacirrhosis |
| spellingShingle | Raffaele Brustia Mohamed Bouattour Manon Allaire Marie Lequoy Clémence Hollande Hélène Regnault Lorraine Blaise Nathalie Ganne-Carrié Valérie Vilgrain Edouard Larrey Chetana Lim Olivier Scatton Sanaa El Mouhadi Violaine Ozenne François Paye Pierre Balladur Anthony Dohan Pierre-Philippe Massault Stanislas Pol Marco Dioguardi Burgio Ailton Sepulveda Francois Cauchy Alain Luciani Daniele Sommacale Vincent Leroy Julien Calderaro Francoise Roudot-Thoraval Jean-Charles Nault Giuliana Amaddeo Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later? Annals of Hepatology 2019-nCoV COVID-19 Management Hepatocellular carcinoma cirrhosis |
| title | Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later? |
| title_full | Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later? |
| title_fullStr | Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later? |
| title_full_unstemmed | Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later? |
| title_short | Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later? |
| title_sort | impact of covid 19 on the management of hepatocellular carcinoma in a high prevalence area what s new 12 months later |
| topic | 2019-nCoV COVID-19 Management Hepatocellular carcinoma cirrhosis |
| url | http://www.sciencedirect.com/science/article/pii/S1665268123002442 |
| work_keys_str_mv | AT raffaelebrustia impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT mohamedbouattour impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT manonallaire impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT marielequoy impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT clemencehollande impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT heleneregnault impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT lorraineblaise impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT nathaliegannecarrie impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT valerievilgrain impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT edouardlarrey impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT chetanalim impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT olivierscatton impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT sanaaelmouhadi impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT violaineozenne impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT francoispaye impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT pierreballadur impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT anthonydohan impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT pierrephilippemassault impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT stanislaspol impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT marcodioguardiburgio impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT ailtonsepulveda impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT francoiscauchy impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT alainluciani impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT danielesommacale impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT vincentleroy impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT juliencalderaro impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT francoiseroudotthoraval impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT jeancharlesnault impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater AT giulianaamaddeo impactofcovid19onthemanagementofhepatocellularcarcinomainahighprevalenceareawhatsnew12monthslater |